Eris to acquire branded formulations of Biocon subsidiary for Rs 1242 crore – Times of India

by The Technical Blogs


Biocon Biologics is selling its branded formulations business to Mumbai-based Eris Lifesciences for Rs 1242 crore.
With the deal, Eris will jumpstart its entry into the Rs 30,000+ crore injectables market in India, and acquire two major insulin brands – Basalog and Insugen.
This acquisition will also mark Eris’ entry into oncology and critical care, says a company statement.
Under this deal, it has also signed a 10-year supply agreement with the Biocon subsidiary. The Biocon product range will continue to be manufactured and supplied to Eris for commercialization in India.
This acquisition also provides immediate synergies with the recently acquired Swiss Parenterals business, it adds.
The Biocon product range can be quickly scaled up by leveraging the product portfolio of Swiss, which consists of 240+ unique molecules. The combination of the two deals also provides margin expansion opportunities through insourcing/ technology transfer of manufacturing to Swiss’ facilities.


Source link

Related Posts

Leave a Comment

Recent Posts

Pigeons swarm Las Vegas neighborhood, nesting at church Study finds adult female elk are badass and can’t be... Vacancy: some more elephants needed in the bush THE TECHNICAL BLOGS

Our Policies

Userful Links

Shop Stores

Copyright @2020  All Right Reserved - Designed and Developed by DSF SEO COMPANY